Biopharmaceutical Manufacturing: The Challenge of Global Regulatory Compliance - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Biopharmaceutical Manufacturing: The Challenge of Global Regulatory Compliance
This article provides an overview of regulatory issues facing companies that seek to market their biopharmaceutical agents globally, including a trend toward harmonization of requirements as well as the differences in rules concerning applications, GMP standards, and communication with reviewers.

Pharmaceutical Technology


1. History and Future of ICH,, accessed November 1, 2007.

2. Synopsis of ICH Guidelines and Topics, May 18, 2004,

3. FDA, Guideline for Drug Master Files (Bethesda, MD, Sept. 1989).

4. S.M. Wheelwright and H. Kosaku, Changes to the Japanese Pharmaceutical Affairs Law,, accessed Nov. 5, 2007.

5. Committee for Proprietary Medicinal Products, Note for Guidance on Summary of Requirements for Active Substances in Part II of the Dossier (The European Agency for the Evaluation of Medicinal Products, London, UK, Jan. 1998).

6. P. D'Eramo, "Japan's Pharmaceutical Affairs Law (PAL): Opportunities and Challenges,", accessed November 5, 2007.

7. Good Clinical Practice — Human Medicinal Products,, accessed Nov. 7, 2007.

8. M.W. Matthews and R. Winslow, "New FDA Rules will Expedite Testing of Drugs," Wall Street Journal: Eastern Edition, Jan. 12, 2006, pp. –B6.

9. FDA, Compliance Program Guidance Manual: Active Pharmaceutical Ingredient Process Inspection (Bethesda, MD, Feb. 13, 2006).

10. R. Horan, "FDA CGMP Inspections," 2005 FDA CGMP China Training Program (Dec. 14, 2005),, accessed Nov. 4, 2007.

11. A.M. Thayer, "Europe Adopts GMP Regulations," Chem. Eng. News 84 (7), 29–33 (2006).

12. FDA, "Innovation and Continuous Improvement in Pharmaceutical Manufacturing," Pharmaceutical CGMPs for the 21st Century,, accessed Nov. 5, 2007.

13. A. Katsnelson, "FDA and EMEA Pool Scientific Advice," Nat Biotechnol. 22(12), 1490–1491(2004).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here